ArticleBMJ open2022
'I can't understand why others don't screen more': a qualitative study exploring why Australian general practitioners screen for primary aldosteronism.
Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 24 citations in OpenAlex.
- Clinician Decision Making in Managing Primary Aldosteronism: A Qualitative Study.Kidney medicine · 2026Article
- The impact of setting up an endocrine hypertension clinic at a tertiary care hospital in Bangladesh.Journal of human hypertension · 2026Article
- Primary aldosteronism.Nature reviews. Disease primers · 2026Review
- Incidence of Adrenal Masses Eventually Discovered in Patients Screened for Primary Aldosteronism.The Journal of clinical endocrinology and metabolism · 2026Article
- Screening and Diagnosis Trends for Primary Aldosteronism: A Longitudinal Nationwide Cohort Study of 7.8 Million People.medRxiv : the preprint server for health sciences · 2025Article
- Universal Screening for Primary Aldosteronism in Hypertensive Patients: A 2025 Taipei Positional Paper.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
- Is It Possible to Screen for Primary Aldosteronism Effectively in Primary Care?Clinical endocrinology · 2025Observational
- Nationwide, Pragmatic, Direct-to-Patient Primary Aldosteronism Testing Program.Hypertension (Dallas, Tex. : 1979) · 2025Article
- Feasibility of primary aldosteronism diagnosis in initial evaluation without medication withdrawal or confirmatory tests.Endocrine · 2024Article
- Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks.Endocrine reviews · 2024Article
- Psychological Responses of Chinese Medical Students to the COVID-19 Pandemic: Empirical Research Qualitative.Psychology research and behavior management · 2024Article
- Autonomous Aldosterone Secretion in Patients with Adrenal Incidentaloma.Biomedicines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe sought to understand the factors that influence a general practitioner's (GP's) experience of screening for primary aldosteronism (PA) in hypertensive patients.
designA qualitative study, framed by phenomenology, using semistructured interviews that were audiorecorded, transcribed verbatim, entered into NVivo V.12.0 for coding and analysed for emerging themes.
settingMelbourne, Australia.
participantsEligible GPs had received education on PA as part of a previous study. We recruited a purposive sample of 16 GPs (6 females, 10 males) who varied in practice location, clinical experience and the number of patients screened for PA.
resultsAlthough GPs had been educated about PA, they found it challenging to explain the condition to patients and were uncertain about how to screen patients who were already taking antihypertensive medications. Most viewed the screening process to be practical, inexpensive and, by and large, acceptable to their patients. However, they found it inconvenient to alter antihypertensive medications before screening to allow for easier interpretation of the aldosterone-renin ratio. They were also less enthused about screening patients whom they thought fitted a clinical picture of essential hypertension. Knowledge of the screening process, cost and convenience of performing the aldosterone-renin ratio, conceptualisation of risk related to PA, and a desire to improve clinical care were influencing factors that modified the GPs' screening experience.
conclusionOur findings suggest that knowledge gaps, practical limitations of the aldosterone-renin ratio, and errors in diagnostic reasoning were challenges of routine PA screening. Most of these practical barriers could be addressed by relatively simple educational and practice modifications to increase PA screening rates and optimise detection for the most common cause of secondary hypertension in primary care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.